Целью данной статьи является рассмотрение степени изученности имени прилагательного в 

крымскотатарском языке как самостоятельной части речи в лингвистических трудах XIX – XX вв., а также 

анализ основных грамматических категорий имени прилагательного

Afonso, Ana

Alvarez, Arturo

Alvarez, Yolanda

Becker, Claudia

de Groot, Mark C H

Durand, Julie

Fischer, Rainald

Gerlach, Roman

Gil, Miguel

Hasford, Joerg

Hesse, Ulrik

Klungel, Olaf H

Primatesta, Paola

Requena, Gema

Rottenkolber, Marietta

Schlienger, Raymond

Schmiedl, Sven

Slattery, Jim

van Dijk, Liset

Voogd, Eef

PubMed

BACKGROUND: Inhaled, long-acting beta-2-adrenoceptor agonists (LABA) have well-established roles in asthma and/or COPD treatment. Drug utilisation patterns for LABA have been described, but few studies have directly compared LABA use in different countries. We aimed to compare the prevalence of LABA-containing prescriptions in five European countries using a standardised methodology. METHODS: A common study protocol was applied to seven European healthcare record databases (Denmark, Germany, Spain, the Netherlands (2), and the UK (2)) to calculate crude and age- and sex-standardised annual period prevalence rates (PPRs) of LABA-containing prescriptions from 2002-2009. Annual PPRs were stratified by sex, age, and indication (asthma, COPD, asthma and COPD). RESULTS: From 2002-2009, age- and sex-standardised PPRs of patients with LABA-containing medications increased in all databases (58.2%-185.1%). Highest PPRs were found in men ≥ 80 years old and women 70-79 years old. Regarding the three indications, the highest age- and sex-standardised PPRs in all databases were found in patients with "asthma and COPD" but with large inter-country variation. In those with asthma or COPD, lower PPRs and smaller inter-country variations were found. For all three indications, PPRs for LABA-containing prescriptions increased with age. CONCLUSIONS: Using a standardised protocol that allowed direct inter-country comparisons, we found highest rates of LABA-containing prescriptions in elderly patients and distinct differences in the increased utilisation of LABA-containing prescriptions within the study period throughout the five European countries

Sub Pharmacotherapy, Theoretical

Sub Gen. Pharmacoepi and Clinical Pharm

Pharmacoepidemiology and Clinical Pharmacology

NARCIS 

Time trends of period prevalence rates of patients with inhaled long-acting beta-2-agonists-containing prescriptions: a European comparative database study

Inhaled, long-acting beta-2-adrenoceptor agonists (LABA) have well-established roles in asthma and/or COPD treatment. Drug utilisation patterns for LABA have been described, but few studies have directly compared LABA use in different countries. We aimed to compare the prevalence of LABA-containing prescriptions in five European countries using a standardised methodology.; A common study protocol was applied to seven European healthcare record databases (Denmark, Germany, Spain, the Netherlands (2), and the UK (2)) to calculate crude and age- and sex-standardised annual period prevalence rates (PPRs) of LABA-containing prescriptions from 2002-2009. Annual PPRs were stratified by sex, age, and indication (asthma, COPD, asthma and COPD).; From 2002-2009, age- and sex-standardised PPRs of patients with LABA-containing medications increased in all databases (58.2%-185.1%). Highest PPRs were found in men ≥ 80 years old and women 70-79 years old. Regarding the three indications, the highest age- and sex-standardised PPRs in all databases were found in patients with "asthma and COPD" but with large inter-country variation. In those with asthma or COPD, lower PPRs and smaller inter-country variations were found. For all three indications, PPRs for LABA-containing prescriptions increased with age.; Using a standardised protocol that allowed direct inter-country comparisons, we found highest rates of LABA-containing prescriptions in elderly patients and distinct differences in the increased utilisation of LABA-containing prescriptions within the study period throughout the five European countries

de Groot, Mark C. H.

Klungel, Olaf H.

edoc

<div>BackgroundInhaled, long-acting beta-2-adrenoceptor agonists (LABA) have well-established roles in asthma and/or COPD treatment. Drug utilisation patterns for LABA have been described, but few studies have directly compared LABA use in different countries. We aimed to compare the prevalence of LABA-containing prescriptions in five European countries using a standardised methodology.MethodsA common study protocol was applied to seven European healthcare record databases (Denmark, Germany, Spain, the Netherlands (2), and the UK (2)) to calculate crude and age- and sex-standardised annual period prevalence rates (PPRs) of LABA-containing prescriptions from 2002–2009. Annual PPRs were stratified by sex, age, and indication (asthma, COPD, asthma and COPD).ResultsFrom 2002–2009, age- and sex-standardised PPRs of patients with LABA-containing medications increased in all databases (58.2%–185.1%). Highest PPRs were found in men ≥ 80 years old and women 70–79 years old. Regarding the three indications, the highest age- and sex-standardised PPRs in all databases were found in patients with “asthma and COPD” but with large inter-country variation. In those with asthma or COPD, lower PPRs and smaller inter-country variations were found. For all three indications, PPRs for LABA-containing prescriptions increased with age.ConclusionsUsing a standardised protocol that allowed direct inter-country comparisons, we found highest rates of LABA-containing prescriptions in elderly patients and distinct differences in the increased utilisation of LABA-containing prescriptions within the study period throughout the five European countries.</div

Marietta Rottenkolber (624530)

Eef Voogd (694942)

Liset van Dijk (466723)

Paola Primatesta (306387)

Claudia Becker (262736)

Raymond Schlienger (694943)

Mark C. H. de Groot (694944)

Yolanda Alvarez (37717)

Julie Durand (694945)

Jim Slattery (694946)

Ana Afonso (664960)

Gema Requena (694947)

Miguel Gil (694948)

Arturo Alvarez (694949)

Ulrik Hesse (694950)

Roman Gerlach (624526)

Joerg Hasford (624529)

Rainald Fischer (308663)

Olaf H. Klungel (179496)

Sven Schmiedl (624525)

The Francis Crick Institute

Time Trends of Period Prevalence Rates of Patients with Inhaled Long-Acting Beta-2-Agonists-Containing Prescriptions: A European Comparative Database Study

Marietta Rottenkolber

Eef Voogd

Liset van Dijk

Paola Primatesta

Claudia Becker

Raymond Schlienger

Mark C. H. de Groot

Yolanda Alvarez

Julie Durand

Jim Slattery

Ana Afonso

Gema Requena

Miguel Gil

Arturo Alvarez

Ulrik Hesse

Roman Gerlach

Joerg Hasford

Rainald Fischer

Olaf H. Klungel

Sven Schmiedl

Crossref

PLoS ONE

Background Inhaled, long-acting beta-2-adrenoceptor agonists (LABA) have well-established roles in asthma and/or COPD treatment. Drug utilisation patterns for LABA have been described, but few studies have directly compared LABA use in different countries. We aimed to compare the prevalence of LABA-containing prescriptions in five European countries using a standardised methodology. Methods A common study protocol was applied to seven European healthcare record databases (Denmark, Germany, Spain, the Netherlands (2), and the UK (2)) to calculate crude and age-and sex-standardised annual period prevalence rates (PPRs) of LABA-containing prescriptions from 2002-2009. Annual PPRs were stratified by sex, age, and indication (asthma, COPD, asthma and COPD). Results From 2002-2009, age-and sex-standardised PPRs of patients with LABA-containing medications increased in all databases (58.2%-185.1%). Highest PPRs were found in men >= 80 years old and women 70-79 years old. Regarding the three indications, the highest age-and sex-standardised PPRs in all databases were found in patients with "asthma and COPD" but with large inter-country variation. In those with asthma or COPD, lower PPRs and smaller inter-country variations were found. For all three indications, PPRs for LABA-containing prescriptions increased with age. Conclusions Using a standardised protocol that allowed direct inter-country comparisons, we found highest rates of LABA-containing prescriptions in elderly patients and distinct differences in the increased utilisation of LABA-containing prescriptions within the study period throughout the five European countries

Dijk, Liset van

Groot, Mark C. H. de

Universität München: Elektronischen Publikationen

English

Background: Inhaled, long-acting beta-2-adrenoceptor agonists (LABA) have well-established roles in asthma and/or COPD treatment. Drug utilisation patterns for LABA have been described, but few studies have directly compared LABA use in different countries. We aimed to compare the prevalence of LABA-containing prescriptions in five European countries using a standardised methodology. Methods: A common study protocol was applied to seven European healthcare record databases (Denmark, Germany, Spain, the Netherlands (2), and the UK (2)) to calculate crude and age- and sex-standardised annual period prevalence rates (PPRs) of LABA-containing prescriptions from 2002–2009. Annual PPRs were stratified by sex, age, and indication (asthma, COPD, asthma and COPD). Results: From 2002–2009, age- and sex-standardised PPRs of patients with LABA-containing medications increased in all databases (58.2%–185.1%). Highest PPRs were found in men ≥ 80 years old and women 70–79 years old. Regarding the three indications, the highest age- and sex-standardised PPRs in all databases were found in patients with “asthma and COPD” but with large inter-country variation. In those with asthma or COPD, lower PPRs and smaller inter-country variations were found. For all three indications, PPRs for LABA-containing prescriptions increased with age. Conclusions: Using a standardised protocol that allowed direct inter-country comparisons, we found highest rates of LABA-containing prescriptions in elderly patients and distinct differences in the increased utilisation of LABA-containing prescriptions within the study period throughout the five European countries. (aut. ref.

Rottenkolber, M.

Voogd, E.

Dijk, L. van

Primatesta, P.

Becker, C.

Schlienger, R.

Groot, M.C.H. de

Alvarez, Y.

Durand, J.

Slattery, J.

Afonso, A.

Requena, G.

Gil, M.

Alvarez, A.

Hesse, U.

Gerlach, R.

Hasford, J.

Fischer, R.

Klungel, O.H.

Schmiedl, S.

Time trends of period prevalence rates of patients with inhaled long-acting beta-2-agonists-containing prescriptions: a European comparative database study.

Utrecht University Repository

Open Access LMU ( Ludwig-Maximilians-Univ. München)

https://figshare.com/articles/_Time_Trends_of_Period_Prevalence_Rates_of_Patients_with_Inhaled_Long_Acting_Beta_2_Agonists_Containing_Prescriptions_A_European_Comparative_Database_Study_/1322419